Novel Variants Near the Central Domain of RYR1 in Two Malignant Hyperthermia-Susceptible Families from Taiwan

BACKGROUND: Our primary objective was to detect malignant hyperthermia (MH)-susceptible persons and thereby prevent MH episodes. We identified variants in the ryanodine receptor isoform 1 using molecular pedigree analysis. METHODS: Nineteen exons covering major hotspots were chosen for the primary screening by polymerase chain reaction, denaturing high performance liquid chromatography, and confirmed by direct sequencing. RESULTS: Three novel variants involving amino acid changes were identified in two unrelated families as Met2698Arg, Glu2724Lys in exon 51 and Leu2785Val in exon 53. CONCLUSIONS: Three novel ryanodine receptor isoform 1 variants located either near or within the central domain might predispose carriers to MH.

[1]  R. Robinson,et al.  Mutations in RYR1 in malignant hyperthermia and central core disease , 2006, Human mutation.

[2]  A. Covacci,et al.  Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia , 2006, Human mutation.

[3]  M. Klein,et al.  Characterization of Ryanodine Receptor–mediated Calcium Release in Human B Cells: Relevance to Diagnostic Testing for Malignant Hyperthermia , 2006, Anesthesiology.

[4]  Y. Hayashi,et al.  Malignant Hyperthermia in Japan: Mutation Screening of the Entire Ryanodine Receptor Type 1 Gene Coding Region by Direct Sequencing , 2006, Anesthesiology.

[5]  H. Yeh,et al.  Denaturing High Performance Liquid Chromatography Screening of Ryanodine Receptor Type 1 Gene in Patients with Malignant Hyperthermia in Taiwan and Identification of a Novel Mutation (Y522C) , 2005, Anesthesia and analgesia.

[6]  R. Litman,et al.  Malignant hyperthermia: update on susceptibility testing. , 2005, JAMA.

[7]  T. Nelson,et al.  Malignant Hyperthermia in North America: Genetic Screening of the Three Hot Spots in the Type I Ryanodine Receptor Gene , 2004, Anesthesiology.

[8]  M. Siegemund,et al.  Molecular Genetic Testing for Malignant Hyperthermia Susceptibility , 2004, Anesthesiology.

[9]  D. Venzon,et al.  Patients with Malignant Hyperthermia Demonstrate an Altered Calcium Control Mechanism in B Lymphocytes , 2002, Anesthesiology.

[10]  J. Antognini,et al.  Testing for Malignant Hyperthermia , 2002, Anesthesiology.

[11]  A. Urwyler,et al.  B-lymphocytes from Malignant Hyperthermia-susceptible Patients Have an Increased Sensitivity to Skeletal Muscle Ryanodine Receptor Activators* , 2001, The Journal of Biological Chemistry.

[12]  A. Urwyler,et al.  Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. , 2001, British journal of anaesthesia.

[13]  F. Lehmann-Horn,et al.  Genetics and pathogenesis of malignant hyperthermia , 2000, Muscle & nerve.

[14]  A. Kunselman,et al.  The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. , 1998, Anesthesiology.

[15]  A. Kunselman,et al.  The Sensitivity and Specificity of the Caffeine‐Halothane Contracture Test: A Report from the North American Malignant Hyperthermia Registry , 1998 .

[16]  F. Lehmann-Horn,et al.  In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low‐risk subjects , 1997, Acta anaesthesiologica Scandinavica.

[17]  A. Herrmann-Frank,et al.  Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant-hyperthermia-susceptible muscle. , 1996, The Biochemical journal.

[18]  A. Localio,et al.  A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.

[19]  G. Comi,et al.  Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia , 1998, Human mutation.